Predicting and Diagnosing Patients with Autoimmune Disease

Technology:
2007-003

Inventors:
Dr. Patrick Gaffney, Dr. Kathy Moser, Dr. Robert Graham and David Altshuler

Invention Description:
The OMRF invention relates to methods of predicting and diagnosing autoimmune disease based on the presence or absence of single nucleotide polymorphisms (SNPs). The inventors have identified at least five distinct SNPs within the Tumor necrosis factor, alpha-induced protein 3 (TNFAIP3) gene that have a significant statistical correlation with Systemic Lupus Erythematosus (SLE). The inventors propose that by examining these SNPs, it is possible to identify those subjects with SLE, as well as those at risk of developing SLE and other autoimmune diseases (Sjogren's syndrome, rheumatoid arthritis,etc.).

Market Application:
In lupus, the body's immune system mistakenly attacks its own tissues and organs. It affects as many as 2 million Americans and has no known cure. Diagnosis is a complicated process of elimination and evaluation of symptom profiles. A better means of diagnosing SLE would mark a major step forward in patient care.

Features, Benefits, and Advantages:
OMRF technology provides a validated candidate marker panel for diagnosis of SLE.

Intellectual Property:
US Patent 8,008,013

Stage of Development
We are currently seeking industry partners to collaborate with us (in the form of research collaboration, licensing etc.) to develop and commercialize this technology.

OMRF

Contact:
Deborah Moorad-Watts, Licensing & Marketing Associate • 755 Research Parkway, Suite 410
Oklahoma City, OK 73104-3600 • 405.271.1741 • Deborah-Moorad@omrf.org